<--- Back to Details
First PageDocument Content
Medical emergencies / Peptides / Angioedema / Hereditary angioedema / C1-inhibitor / Urticaria / Danazol / Acquired C1 esterase inhibitor deficiency / Laryngopharyngeal reflux / Medicine / Health / Complement deficiency
Medical emergencies
Peptides
Angioedema
Hereditary angioedema
C1-inhibitor
Urticaria
Danazol
Acquired C1 esterase inhibitor deficiency
Laryngopharyngeal reflux
Medicine
Health
Complement deficiency

Farkas Allergy, Asthma & Clinical Immunology 2010, 6:19 http://www.aacijournal.com/contentREVIEW ALLERGY, ASTHMA & CLINICAL

Add to Reading List

Source URL: www.aacijournal.com

Download Document from Source Website

File Size: 292,26 KB

Share Document on Facebook

Similar Documents

[Product Monograph Template - Schedule D]

[Product Monograph Template - Schedule D]

DocID: 1qWQL - View Document

News Releases  Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

Microsoft Word - CINRYZE.Product Monographdoc

Microsoft Word - CINRYZE.Product Monographdoc

DocID: 1qE2h - View Document

Microsoft Word - FIRAZYR.Product Monographdoc

Microsoft Word - FIRAZYR.Product Monographdoc

DocID: 1qA9x - View Document

Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop

Fact Sheet CSL BehringCSL Sales $5.5 Billion CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop

DocID: 1pVHk - View Document